GSK agrees to some US settlements on Paxil birth defect claims
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has confirmed to Scrip that it has reached agreement to settle "certain cases" in which the plaintiffs alleged that the company failed to sufficiently warn doctors and pregnant women that its antidepressant Paxil (paroxetine) could cause birth defects, but the settlement amounts remain confidential. Some cases remain pending and others are scheduled for trial this autumn.